drugset
drugset / Trial / NCT06104423

Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

NCT06104423 ↗

Phase 4 Completed 266 enrolled Menarini International Operations Luxembourg SA
Non-randomizedSequentialOpen-labelTreatment

Summary

Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.

Timeline

Start
2023-10-02
Primary completion
2024-02-19
Completion
2024-02-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nebivolol Other / unclassified 5 mg Oral
Comparator Ramipril Small molecule 2.5 mg Oral
Comparator Ramipril Small molecule 5 mg Oral
Comparator Ramipril Small molecule 10 mg Oral

Indications

hypertensive disorder